Ivo combo beats Tevimbra, but can it beat Keytruda?
The PD-1 x VEGF molecule's latest win comes from Akeso's Harmoni-6 trial.
ELCC 2025 – BioNTech impresses in small-cell lung
In first-line SCLC BNT327 looks better than Tecentriq, but data will need to be replicated outside China.
Summit looks to repeat ivo's Chinese success
Akeso scored in the Harmoni-A trial, and now Summit must do the same in Harmoni.
BioNTech's pivotal bispecifics plan take shape
Phase 3 development plans for BNT327 and ivonescimab start to diverge.
BioNTech puts a ring on Biotheus
A year after paying $55m to license Biotheus’s PD-L1/VEGF, BioNTech is going all in for $800m.
Looking for an ivonescimab encore
What similarly acting projects are still unpartnered?
